Vilon dosing & administration
Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
200–500 mcg
Frequency
Once daily
Duration
5–10 day course
Common Khavinson-style introductory protocol for the KE (Lys-Glu) immune bioregulator; courses repeated 2–3 times yearly [6]. Research use only — no approved product.
500 mcg
Frequency
Once daily
Duration
10–12 day course
Typical full-course practice dose; cycle repeated every 3–6 months [6].
Timing
Best time to take
Administer Vilon at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Vilon injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Vilon should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Vilon in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Vilon should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Vilon. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Injection site reaction, Mild fatigue, Mild headache, Digestive changes
Less common: Flu-like symptoms
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Vilon
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Vilon should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Immunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) — Vilon's immunostimulatory effects may counteract immunosuppression — Use with caution—discuss with your healthcare provider.
- High-dose corticosteroids — may interfere with Vilon's T-cell activation and cytokine regulation mechanisms — Use with caution—discuss with your healthcare provider.
- Other potent immunostimulants at high doses without medical supervision — risk of immune overactivation — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Khavinson VK, Linkova NS, Ashapkin VV · 2023
Vilon peptide (KE) regulates longevity genes by activating SIRT1 and suppressing aging-related PARP1/PARP2, with anti-aging effects mediated through DNA binding.
Linkova N, Khavinson V, Diatlova A · 2023
Research (2023) on vilon contributes important scientific knowledge about its biological and pharmacological properties.
Avolio F, Martinotti S, Khavinson VK · 2022
Chonluten peptide and other tissue-specific peptides suppress TNF and inflammatory cytokines in immune cells, acting as natural inducers of inflammation tolerance during infections and tissue damage.
Sevostianova NN, Linkova NS, Polyakova VO · 2013
Research (2013) on vilon contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VKh, Rybakina EG, Malinin VV · 2002
Research (2002) on vilon contributes important scientific knowledge about its biological and pharmacological properties.
Project Biohacking (Khavinson bioregulator reference) · 2024
Head to head
Vilon compared
Want the full picture?
The complete Vilon research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.